Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

NCT07315854 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer (GC)
Gastroesophageal Junction Cancer
Advanced Gastric Cancer
Metastatic Gastric Cancer

Interventions

DRUG: Iparomlimab and Tuvonralimab (QL1706)
DRUG: SOX Chemotherapy

Sponsor

Beijing Friendship Hospital